AIV Logo AIV Assistant

Loading...

 Logo Reviva Pharmaceuticals Holdings, Inc. - RVPH Open Reviva Pharmaceuticals Holdings, Inc. in new tab

0.50 USD
EPS
-0.64
P/B
-85.67
ROE
-916.17
Beta
-0.08
Target Price
5.38 USD

0.5042 USD

0.504 USD

Daily: +0.00%
Key Metrics

Earnings date: Nov. 13, 2025

EPS: -0.64

Book Value: -0.01

Price to Book: -85.67

Debt/Equity: 56.38

% Insiders: 5.133%

Estimates

Forward P/E: -0.74

Forward EPS: -0.81

Target Mean Price: 5.38

DCF Valuation

Tweak assumptions to recompute fair value for Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

 Logo About Reviva Pharmaceuticals Holdings, Inc. - (RVPH)

Country: United States

Sector: Health Care

Website: http://www.revivapharma.com

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

Exchange Ticker
NCM (Australia) RVPH

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion